TSX Venture: RVV OTCQB: RVVTF

Size: px
Start display at page:

Download "TSX Venture: RVV OTCQB: RVVTF"

Transcription

1 TSX Venture: RVV OTCQB: RVVTF The image part with relationship ID rid3 was not found in the file Annual General and Special Meeting of Shareholders December 19, 2017 Revive Therapeutics Ltd. Office:

2 FORWARD LOOKING STATEMENTS Certain statements contained in this presentation constitute forward-looking information within the meaning of securities laws. Forwardlooking information may relate to our future outlook and anticipated events or results and may include statements regarding our future financial position, business strategy, budgets, litigation, projected costs, capital expenditures, financial results, taxes and plans and objectives. In some cases, forward-looking information can be identified by terms such as may, will, should, expect, plan, anticipate, believe, intend, estimate, predict, potential, continue or other similar expressions concerning matters that are not historical facts. These statements are based on certain factors and assumptions regarding, among other things, expected growth, results of operations, performance, and business prospects and opportunities. While we consider these assumptions to be reasonable based on information currently available to us, they may prove to be incorrect. Forward looking-information is also subject to certain factors, including risks and uncertainties that could cause actual results to differ materially from what we currently expect. These factors include, among other things, the availability of funds and resources to pursue development projects, the successful and timely completion of clinical studies, and the ability to take advantage of business opportunities, the granting of necessary approvals by regulatory authorities, and general economic, market and business conditions. For more exhaustive information on these risks and uncertainties you should refer to our most recently filed Annual Information Form which is available at Forward-looking information contained in this presentation is based on our current estimates, expectations and projections, which we believe are reasonable as of the current date. You should not place undue importance on forward-looking information and should not rely upon this information as of any other date. While we may elect to, we are under no obligation and do not undertake to update this information at any particular time.

3 Revive Therapeutics Commercializing novel medical cannabis products and cannabinoid pharmaceuticals Proprietary delivery technology and novel cannabinoid pharmaceuticals pipeline Targeting +$50 billion global medical cannabis market and global pharmaceuticals market Partnering with licensed medical cannabis producers and pharmaceutical companies Experienced management team, scientific & clinical advisors, strategic relationships, intellectual property Unique opportunity for investors to invest in the medical cannabis and cannabinoid pharmaceuticals market

4 Recap of Corporate Objectives Advanced drug and cannabinoid-focused product pipeline Initiated US FDA Phase 2 study in Cystinuria Strengthened cannabinoid scientific and clinical team with additions of Dr. Arun Sanyal, Dr. Scott Friedman, Dr. Ram Subramanian, Dr. Pritesh Kumar, Dr. Yanlin Wang Engaged in a Research and Option to License agreement with the Wisconsin Alumni Research Foundation (WARF) for unique delivery system for cannabinoids Engaged in a Sponsored Research agreement with the University of Wisconsin-Madison to conduct research and development of a novel cannabinoid delivery technology Licensed patent from South Carolina Research Foundation for the use of cannabidiol in the treatment of autoimmune hepatitis (rare liver disease / FDA orphan designation potential)

5 Recap of Corporate Objectives Research collaborations with Phytosciences and Sanyal Biotechnology for liver diseases Validated cannabinoid delivery system for potential use in pain, dermatology, wound healing Initiated feasibility of Blockchain / Artificial Intelligence medical cannabis patient-focused program Engaged in a License and Development Agreement with Datametrex s subsidiary, Nexalogy, for AI component of the medical cannabis patient-focused program Collaboration with Health Canada Licensed Dealer for medical cannabis (Chemi Pharmaceutical Inc.) Broadened investment community awareness Increased trading volume and liquidity (Avg. 3-month volume ~ 700,000 shares/day)

6 2018 Corporate Objectives Expand development and commercialization of cannabinoid-based products via licensing, acquisitions, and partnerships Partner with Canadian licensed producers ( LP ) of medical cannabis pursuant to the Access to Cannabis for Medical Purposes Regulations ("ACMPR") Commercialize medical cannabis products supported by pre-clinical and human observatory studies (i.e. liver diseases, pain, dermatology) Advance clinical development of pharmaceutical cannabinoid product pipeline for US FDA approval with orphan drug designation and IND (i.e. rare diseases focus)

7 2018 Corporate Objectives Advance development in liver diseases with Sanyal Biotech to support US FDA IND for human clinical studies and to support commercialization of medical cannabis products Partner with LPs and Pharma for cannabinoid delivery system and product pipeline Advance development and commercialization of medical cannabis patient-focused program enabled by blockchain and AI Improve balance sheet to execute on strategy via warrant exercise, private placements/prospectus, pharma and LP partnerships Increase investment community awareness and educate investors on risk/reward and value proposition of Revive

8 Peer Analysis Show Revive Undervalued Source: Danny Deadlock, Microcap.com

9 KEY FINANCIAL INFORMATION Ticker Symbols RVV (TSX Venture) RVVTF (OTCQB) Share Price CAD $0.305 (December 18, 2017) 52 week High/Low CAD $0.44 / $0.10 Capital Structure 55,788,667 common shares (62,889,983 fully-diluted) Market Cap CAD ~ $17,000,000 Cash and Cash Equivalents CAD $1,406,469 (as of September 30, 2017) Cash Burn/Month CAD ~ $125,000 Warrants: 3,907,565 (expire June 18, 2018) 50,400 Finder s (one common share and one-half Stock Options: 3,118,151 stock options $0.60; $0.66; $0.30; $0.28; $0.20; $0.335)

10 Thank you 2017 Annual General and Special Meeting of Shareholers Revive Therapeutics Ltd. Office:

TSX Venture: RVV OTCQB: RVVTF

TSX Venture: RVV OTCQB: RVVTF TSX Venture: RVV OTCQB: RVVTF Corporate Presentation June 2018 Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com FORWARD LOOKING STATEMENTS Certain statements contained in this

More information

TSX Venture: RVV OTCQB: RVVTF

TSX Venture: RVV OTCQB: RVVTF TSX Venture: RVV OTCQB: RVVTF Corporate Presentation February 2018 Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com FORWARD LOOKING STATEMENTS Certain statements contained in

More information

SPECIALTY MEDICAL CANNABIS COMPANY

SPECIALTY MEDICAL CANNABIS COMPANY SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward

More information

TSX Venture: RVV OTCQB: RVVTF

TSX Venture: RVV OTCQB: RVVTF TSX Venture: RVV OTCQB: RVVTF Corporate Presentation November 2017 Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com FORWARD LOOKING STATEMENTS Certain statements contained in

More information

MEDICAL CANNABIS COMPANY

MEDICAL CANNABIS COMPANY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - June 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward looking statements

More information

SPECIALTY MEDICAL CANNABIS COMPANY

SPECIALTY MEDICAL CANNABIS COMPANY SPECIALTY MEDICAL CANNABIS COMPANY TSX Venture: RVV OTCQB: RVVTF Corporate Presentation - August 2018 ReviveThera.com Revive Therapeutics Ltd. Office: 905-605-5535 E-mail: info@revivethera.com Forward

More information

Investor Presentation

Investor Presentation Investor Presentation February 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities

More information

INVESTOR PRESENTATION

INVESTOR PRESENTATION INVESTOR PRESENTATION May 2018 2 FORWARD-LOOKING INFORMATION The following presentation contains statements that are considered forward-looking information ( FLI ) within the meaning of securities regulation.

More information

Investor Presentation

Investor Presentation ASX:THC B u i l d i n g a M e d i c i n a l C a n n a b i s B u s i n e s s Investor Presentation November 2017 DISCLAIMER The material in this presentation (material) is not and does not constitute an

More information

Tamsulosin Hydrochloride 0.4 mg Capsule

Tamsulosin Hydrochloride 0.4 mg Capsule Tamsulosin Hydrochloride 0.4 mg Capsule, Tamsulosin Hydrochloride 0.4 mg Capsule India, Tamsulosin Hydrochloride 0.4 mg Capsule manufacturers India, side effects Tamsulosin Hydrochloride 0.4 mg Capsule

More information

COMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing

COMPANY PRESENTATION JULY Bob Bechard Executive Vice-President Corporate Development & Licensing COMPANY PRESENTATION JULY 2018 Bob Bechard Executive Vice-President Corporate Development & Licensing Forward Looking Statements Some statements in this release may contain forward-looking information.

More information

Dynavax Corporate Presentation

Dynavax Corporate Presentation Dynavax Corporate Presentation Forward-Looking Statements This presentation contains forward-looking statements, including statements regarding our HEPLISAV-B TM regulatory submissions, product profile,

More information

Investor Presentation May 2, 2017

Investor Presentation May 2, 2017 CSE: TBP OTC: GRPOF Investor Presentation May 2, 2017 Forward Looking Statements This presentation contains certain forward-looking statements that may involve a number of risks and uncertainties. Actual

More information

Forward-Looking Statements

Forward-Looking Statements Investor Presentation May 2012 Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933, as amended.

More information

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014

Acquisition of Novartis Influenza Vaccines Business. 27 th October 2014 1 Acquisition of Novartis Influenza Vaccines Business 27 th October 2014 2 Legal Notice Forward looking statements The materials in this presentation speak only as of the date of these materials, and include

More information

DARA Reports Year-End 2012 Financial Results

DARA Reports Year-End 2012 Financial Results April 1, 2013 DARA Reports Year-End 2012 Financial Results Company Provides a Commercial Portfolio and Development Pipeline Business Update RALEIGH, NC -- (MARKETWIRE) -- 04/01/13 -- DARA BioSciences,

More information

Corporate Presentation. October 2017

Corporate Presentation. October 2017 AEPP Breakthrough technology for women s cancers Corporate Presentation October 2017 Oncolix 2017 1 Safe Harbor Certain of the statements and the projections set forth in this presentation constitute forward-looking

More information

Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy

Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Inducing Tumor-Specific Ischemic Necrosis to Enhance the Efficacy of Checkpoint Inhibitors and Chemotherapy Company Overview, September 2018 Safe Harbor Statement This presentation contains forward-looking

More information

For personal use only

For personal use only ASX RELEASE (23 rd March 2018) AGM PowerPoint Presentaion In accordance with the requirements of Listing Rule 3.1 we submit the attached material being distributed at the Company s Annual General Meeting

More information

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2018 Financial Results and Provides Business Update IMPLANT 4 trial of nolasiban in IVF starting in Q4 2018, European MAA filing expected late 2019 24-week data from Phase

More information

COMPANY PRESENTATION. Bernard Fortier, CEO

COMPANY PRESENTATION. Bernard Fortier, CEO COMPANY PRESENTATION Bernard Fortier, CEO Forward Looking Statements Some statements in this release may contain forward-looking information. All statements, other than of historical fact, that address

More information

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS

SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS SPHERIX Investor Relations Phone: (301) 897-2564 Email: info@spherix.com SPHERIX ANNOUNCES FIRST QUARTER 2010 FINANCIAL RESULTS BETHESDA, MD, May 21, 2010 - Spherix Incorporated (NASDAQ CM: SPEX), an innovator

More information

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016

ADAPTIMMUNE INVESTOR PRESENTATION. August 2016 ADAPTIMMUNE INVESTOR PRESENTATION August 2016 DISCLAIMER This presentation contains forward-looking statements, as that term is defined under the Private Securities Litigation Reform Act of 1995 (PSLRA),

More information

Dawson James Conference

Dawson James Conference Dawson James Conference October 2018 Forward-looking Statements Except for historical information, this presentation contains forward-looking statements, which reflect IMV s current expectations regarding

More information

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET

AVEO Oncology Announces Strategic Restructuring. AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET NEWS RELEASE FOR IMMEDIATE RELEASE AVEO Oncology Announces Strategic Restructuring AVEO to Host Conference Call Wednesday, June 5 at 8:30 a.m. ET CAMBRIDGE, Mass., June 4, 2013 AVEO Oncology (NASDAQ: AVEO)

More information

Investor Presentation June 2012 NASDAQ: CEMI

Investor Presentation June 2012 NASDAQ: CEMI Investor Presentation June 2012 NASDAQ: CEMI Forward-Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act

More information

Genomic Health. Kim Popovits, Chairman, CEO and President

Genomic Health. Kim Popovits, Chairman, CEO and President Genomic Health Kim Popovits, Chairman, CEO and President Safe Harbor Statement Various remarks that we make in this presentation that are not historical, including those about our future financial and

More information

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019

Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Acasti Pharma Provides Business Update for the Third Quarter of Fiscal 2019 Planned Enrollment targets achieved in both TRILOGY studies with over 74% of patients randomized at more than 150 clinical sites

More information

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology

XXII: CTP Summarizes Scientific Case for Limiting Nicotine in Cigarettes. Company Update October 15, 2018 Industrial & Consumer Technology Company Update Industrial & Consumer Technology (XXII - $2.81 - Buy) COMPANY NOTE JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com Sales and trading 7 a.m. to 7 p.m. ET,

More information

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update

ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update ObsEva Reports Third Quarter 2017 Financial Results and Provides Business Update - All Three Development Compounds Progressing with Key Clinical Milestones Over the Next 12 Months - Geneva, Switzerland

More information

OncoSec Provides 2018 Business Outlook

OncoSec Provides 2018 Business Outlook January 3, 2018 OncoSec Provides 2018 Business Outlook Complete stage 1 enrollment of PISCES/KEYNOTE-695 clinical trial of ImmunoPulse IL-12 in combination with KEYTRUDA (pembrolizumab) Present preliminary

More information

Corporate Overview. February 2018 NASDAQ: CYTR

Corporate Overview. February 2018 NASDAQ: CYTR Corporate Overview February 2018 NASDAQ: CYTR CytRx Safe Harbor Statement THIS PRESENTATION CONTAINS FORWARD-LOOKING STATEMENTS THAT INVOLVE CERTAIN RISKS AND UNCERTAINTIES. ACTUAL RESULTS COULD DIFFER

More information

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update

ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update ObsEva Reports First Quarter 2018 Financial Results and Provides Business Update -Key First Quarter 2018 Clinical Milestones Achieved Patient randomization completed in Phase 2b EDELWEISS trial of OBE2109

More information

Q3 18 Earnings Supplemental Slides

Q3 18 Earnings Supplemental Slides (Nasdaq: INSY) Q3 18 Earnings Supplemental Slides November 5, 2018 Safe-Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements

More information

Leading Cannabinoid Patient Care in Canada. Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF

Leading Cannabinoid Patient Care in Canada. Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF Leading Cannabinoid Patient Care in Canada Corporate Presentation July 2017 TSXV: CMM OTCQB: CAMDF Forward Looking Statements Except for historical information, this presentation contains forward-looking

More information

Chairman s Address Dr. Richard Treagus

Chairman s Address Dr. Richard Treagus Chairman s Address Dr. Richard Treagus Annual Shareholders Meeting Of Neuren Pharmaceuticals Limited, 30 April 2014 Good morning Ladies and Gentlemen. Welcome to our Annual Shareholders Meeting in Melbourne.

More information

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call

Determined to realize a future in which people with cancer live longer and better than ever before Q Conference Call Reimagining Cancer Treatment Determined to realize a future in which people with cancer live longer and better than ever before Q1 2016 Conference Call 1 Forward-Looking Statements Disclosure This presentation

More information

Diagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015

Diagnostics for the early detection and prevention of colon cancer. Fourth-Quarter 2014 Earnings Call February 24, 2015 Diagnostics for the early detection and prevention of colon cancer Fourth-Quarter 2014 Earnings Call February 24, 2015 Safe Harbor Statement Certain statements made in this presentation contain forward-looking

More information

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End

VeriStrat Poor Patients Show Encouraging Overall Survival and Progression Free Survival Signal; Confirmatory Phase 2 Study Planned by Year-End AVEO and Biodesix Announce Exploratory Analysis of VeriStrat-Selected Patients with Non-Small Cell Lung Cancer in Phase 2 Study of Ficlatuzumab Presented at ESMO 2014 Congress VeriStrat Poor Patients Show

More information

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE

37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE 37 th ANNUAL JP MORGAN HEALTHCARE CONFERENCE January 2019 Safe Harbor Statement This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as

More information

Revolutionizing how advanced heart disease is treated

Revolutionizing how advanced heart disease is treated LEERINK Partners 5th Annual Healthcare Conference Revolutionizing how advanced heart disease is treated NASDAQ: NCVN, TSX: NVC Alexei Marko, CEO February 2016 Forward-Looking Statements Statements contained

More information

which has been used to help the treatment of epilepsy, seizures, alleviate neuropathic pain and muscular dystrophy.

which has been used to help the treatment of epilepsy, seizures, alleviate neuropathic pain and muscular dystrophy. News Release April 10, 2018, Kelowna, BC Marapharm Ventures Inc. To Introduce Organic CBD Health and Wellness Products To Be Featured In Its California Dispensary Marapharm Ventures Inc. (CSE: MDM) (OTCQX:

More information

Intercell and Novartis form world leading strategic partnership to drive vaccines innovation

Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Intercell and Novartis form world leading strategic partnership to drive vaccines innovation Alliance creates opportunity for two strong innovators to combine development efforts in attractive areas Intercell

More information

GW Pharmaceuticals plc. Investor Presentation August 2014

GW Pharmaceuticals plc. Investor Presentation August 2014 GW Pharmaceuticals plc Investor Presentation August 2014 Forward Looking Statements and Disclaimer This presentation contains forward-looking statements. Some of the matters discussed concerning our operations

More information

HILLENBRAND INDUSTRIES INC

HILLENBRAND INDUSTRIES INC HILLENBRAND INDUSTRIES INC FORM 8-K (Unscheduled Material Events) Filed 2/17/2004 For Period Ending 2/13/2004 Address 700 STATE ROUTE 46 E BATESVILLE, Indiana 47006-8835 Telephone 812-934-7000 CIK 0000047518

More information

Mental Toronto Hydro

Mental Toronto Hydro Mental Health @ Shirley Powell, Director, HR Planning, Systems & Rewards Benefits Canada s 2015 Healthy Outcomes Conference June 9-11, 2015 Niagara-on-the-Lake Company Overview Established in 1911 Largest

More information

USPSTF Draft Recommendations Investor Call. October 6, 2015

USPSTF Draft Recommendations Investor Call. October 6, 2015 USPSTF Draft Recommendations Investor Call October 6, 2015 v Safe Harbor Statement Certain statements made in this presentation contain forward-looking statements within the meaning of Section 27A of the

More information

SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018

SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAVARA CORPORATE PRESENTATION (NASDAQ: SVRA) NOVEMBER 2018 SAFE HARBOR STATEMENT Savara Inc. ( Savara or the Company ) cautions you that statements in this presentation that are not a description of historical

More information

Investor presentation. Bioshares Biotech Summit July 2017

Investor presentation. Bioshares Biotech Summit July 2017 Investor presentation Bioshares Biotech Summit 2017 22 July 2017 1 Disclaimer Some of the information in this presentation may refer to Dimerix Limited ( Dimerix or the Company ) based on information available

More information

RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit

RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit RespireRx Pharmaceuticals Inc. Executives Presenting at the International Cannabinoid Derived Pharmaceuticals Summit December 11 12, 2018 Workshops, December 10, 2018 The Revere Hotel 200 Stuart St., Boston,

More information

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations

22nd Century Group, Inc. (XXII - $ Buy) Q1 Far Ahead of Expectations Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.21 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com

More information

Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015

Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 (Nasdaq:EVAR) Corporate Update Simon Hubbert, CEO Bill Kullback, CFO June, 2015 Safe Harbor This presentation contains forward-looking statements as that term is defined in the Private Securities Litigation

More information

PATENCY-1 Top-Line Results

PATENCY-1 Top-Line Results PATENCY-1 Top-Line Results December 13, 2016 2016 Proteon Therapeutics, Inc. Cautionary Note Regarding Forward-Looking Statements This presentation contains statements that are, or may be deemed to be,

More information

Avenue Therapeutics, Inc. May 2017

Avenue Therapeutics, Inc. May 2017 Avenue Therapeutics, Inc. May 2017 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the safe

More information

Investment in MGC Pharmaceuticals

Investment in MGC Pharmaceuticals Investment in MGC Pharmaceuticals Investor Presentation May 2015 Disclaimer This presentation has been prepared by Erin Resources Limited ( Company ). It does not purport to contain all the information

More information

Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update

Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Evofem Biosciences Reports Second Quarter 2018 Financial Results and Provides Corporate Update Phase 3 Trial of Amphora for Hormone-free Contraception Continues to Move Ahead of Schedule; Top Line Data

More information

Q4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO

Q4 Report Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Q4 Report 2018 Webcast February 7, 2019 Presenters: Renée Aguiar-Lucander, CEO Fredrik Johansson, CFO Disclaimer Important information This presentation has been prepared by Calliditas Therapeutics AB

More information

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics

Visionary Private Equity Group is Pleased to Announce its Investment in MEDITE Cancer Diagnostics Dear VPEG Limited Partner, We hope this investor update finds you well. We're pleased to share with you an important update below on the following: Visionary Private Equity Group is Pleased to Announce

More information

VolitionRx Announces First Quarter 2016 Financial Results and Business Update

VolitionRx Announces First Quarter 2016 Financial Results and Business Update May 13, 2016 VolitionRx Announces First Quarter 2016 Financial Results and Business Update NAMUR, Belgium, May 13, 2016 /PRNewswire/ -- VolitionRx Limited (NYSE MKT: VNRX), a life sciences company focused

More information

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A

Slide 1. Financial update and closing remarks. Jesper Brandgaard EVP and CFO. RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 1 Financial update and closing remarks Jesper Brandgaard EVP and CFO RAFAEL DE JESÚS FLORES, Mexico Rafael has haemophilia A Slide 2 Forward-looking statements Novo Nordisk s reports filed with or

More information

Avenue Therapeutics, Inc. September 2016

Avenue Therapeutics, Inc. September 2016 Avenue Therapeutics, Inc. September 2016 Forward Looking Statements Statements in this presentation that are not descriptions of historical facts are forward looking statements within the meaning of the

More information

OWC PHARMACEUTICAL RESEARCH OTCQB:OWCP

OWC PHARMACEUTICAL RESEARCH OTCQB:OWCP OWC PHARMACEUTICAL RESEARCH OTCQB:OWCP Disclaimer This document details business information of OWC Pharmaceuticals Research Corp and/or our wholly-owned Israeli subsidiary, One World Cannabis Ltd. (collectively,

More information

Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results

Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results August 11, 2008 Emisphere Technologies, Inc. Announces 2008 Second Quarter Financial Results Conference Call/Webcast to be Held Monday, August 11 at 10:00 AM EDT CEDAR KNOLLS, N.J., Aug 11, 2008 /PRNewswire-FirstCall

More information

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS

HALOZYME REPORTS SECOND QUARTER 2018 RESULTS Contacts: Robert H. Uhl Managing Director Westwicke Partners, LLC 858-356-5932 robert.uhl@westwicke.com Laurie Stelzer 858-704-8222 ir@halozyme.com FOR IMMEDIATE RELEASE HALOZYME REPORTS SECOND QUARTER

More information

For personal use only

For personal use only AusCann Makes Major Progress Towards Production of Cannabinoid Medicines During FY18 Highlights Undertook comprehensive pharmaceutical development project to create an optimal dosage form cannabinoid medicine

More information

CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer

CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer November 26, 2018 CytoDyn Announces Initiation of Metastatic Triple Negative Breast Cancer Trial and Reiterates Phase 3 Goal in Cancer VANCOUVER, Washington, Nov. 26, 2018 (GLOBE NEWSWIRE) -- CytoDyn Inc.

More information

Growth Conference. October 19, May 2013

Growth Conference. October 19, May 2013 Dawson Corporate James Securities Presentation 3rd Annual Small Cap Growth Conference October 19, 2017 May 2013 Safe Harbor This document contains forward-looking statements within the meaning of the "safe

More information

Merck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference

Merck Announces FDA Approval of KEYTRUDA. Provided to Investors as a Reference Merck Announces FDA Approval of KEYTRUDA Provided to Investors as a Reference Forward-Looking Statement This presentation includes forward-looking statements within the meaning of the safe harbor provisions

More information

Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS

Two-stage study designed to evaluate tolerability and efficacy of pracinostat combined with azacitidine in patients with high and very high risk MDS Helsinn Group and MEI Pharma Announce First Patient Dosed in Phase 2 Dose-Optimization Study of Pracinostat and Azacitidine in Myelodysplastic Syndrome Two-stage study designed to evaluate tolerability

More information

Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results

Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results Eiger BioPharmaceuticals Reports Third Quarter 2016 Financial Results Data from Multi-center, International LOWR HDV (LOnafarnib With Ritonavir in HDV) Phase 2 Program to be Presented at AASLD 2016 Eiger

More information

Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C

Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C Acasti Reports Successful CaPre(R) Phase II TRIFECTA Results Proving Statistically Significant Improvements in Triglycerides & Non-HDL-C CaPre(R) Met All Primary and Key Secondary Endpoints Statistically

More information

Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference

Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference Savient's Pegloticase Data in Treatment-Failure Gout Patients Presented at 72nd Annual Meeting of the American College of Rheumatology Conference EAST BRUNSWICK, N.J., Oct 27, 2008 /PRNewswire-FirstCall

More information

Leading the Next Wave of Biotech Breakthroughs

Leading the Next Wave of Biotech Breakthroughs Leading the Next Wave of Biotech Breakthroughs Corporate Extensive corporate assets Platforms Pipeline Partnerships Building a sustainable global business Platform licenses represent a source of non-dilutive

More information

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015

ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 ST. JUDE MEDICAL / THORATEC TRANSACTION HIGHLIGHTS July 22, 2015 1 FORWARD LOOKING STATEMENT This presentation contains forward-looking statements within the meaning of the Private Securities Litigation

More information

DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75)

DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) Equity Healthcare / Biotechnology Update (December 3, 2015) DelMar Pharmaceuticals Inc. (OTCQX: DMPI, Target Price: $5.75) DelMar Pharmaceuticals, Inc. ( DelMar, OTCQX: DMPI) is a clinical stage biotechnology

More information

Investor Presentation

Investor Presentation Investor Presentation January 2012 Forward Looking Statements Statements contained herein that are not historical facts are forward-looking statements within the meaning of the Securities Act of 1933,

More information

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation

Patrick J. Sullivan Chief Executive Officer. January 9, 2018 Investor Presentation Patrick J. Sullivan Chief Executive Officer January 9, 2018 Investor Presentation Forward Looking Statement This presentation may contain forward-looking statements concerning Insulet's expectations, anticipations,

More information

Slide 1. Investor presentation. London 5 February 2019

Slide 1. Investor presentation. London 5 February 2019 Slide Investor presentation London 5 February 209 Slide 2 Forward-looking statements Novo Nordisk s reports filed with or furnished to the US Securities and Exchange Commission (SEC), including this presentation

More information

AM-125 : Intranasal Betahistine

AM-125 : Intranasal Betahistine AM-125 : Intranasal Betahistine February 3, 2017 NASDAQ: EARS Forward-looking Statements This presentation and the accompanying oral commentary contain forward-looking statements that involve substantial

More information

Nitrazepam. Nitrazepam Tablets TAJ GROUP PHARMACEUTICAL B U S I N E S S. Generics. Active Ingredients: Each tablet contains 10 mg Nitrazepam

Nitrazepam. Nitrazepam Tablets TAJ GROUP PHARMACEUTICAL B U S I N E S S. Generics. Active Ingredients: Each tablet contains 10 mg Nitrazepam Nitrazepam, Nitrazepam India, Nitrazepam manufacturers India, side effects Nitrazepam manufacturers, Taj Pharma India, Nitrazepam overdose, Nitrazepam drug, Nitrazepam composition, Manufacturing Pharmaceutical,

More information

22nd Century Group, Inc. (XXII - $ Buy)

22nd Century Group, Inc. (XXII - $ Buy) Company Update Industrial & Consumer Technology 22nd Century Group, Inc. (XXII - $2.47 - Buy) COMPANY NOTE Estimate Change JAMES McILREE, CFA, Senior Research Analyst, +1-646-465-9034 jmcilree@chardan.com

More information

REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS

REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS REATA PHARMACEUTICALS, INC. ANNOUNCES SECOND QUARTER 2018 FINANCIAL RESULTS AND AN UPDATE ON DEVELOPMENT PROGRAMS IRVING, Texas August 8, 2018 Reata Pharmaceuticals, Inc. (Nasdaq: RETA), a clinical-stage

More information

VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018

VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients. September 2018 VAL-083: Validated DNA-targeting Agent for Underserved Cancer Patients September 2018 Forward-Looking Statements Any statements contained in this presentation that do not describe historical facts may

More information

Corporate Presentation Asia Investment Series March 2018

Corporate Presentation Asia Investment Series March 2018 Corporate Presentation Asia Investment Series March 2018 Safe Harbor Statement Factors Affecting Future Performance This presentation contains "forward-looking" statements within the meaning of the United

More information

Developing Xanamem for Alzheimer s Dementia

Developing Xanamem for Alzheimer s Dementia Developing Xanamem for Alzheimer s Dementia Dr. Bill Ketelbey CEO, Actinogen Medical Investor Presentation March 2015 Forward Statements This presentation has been prepared by Actinogen Limited. ( Actinogen

More information

Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update

Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update Aerpio Reports Fourth Quarter and Full Year 2017 Financial Results and Provides Business Update TIME-2b Clinical Trial of AKB-9778 in Patients with Diabetic Retinopathy Remains on Track Conference Call

More information

For personal use only

For personal use only October 29 th, 2018 RotoGro to Acquire 100% of Canadian Lawful Cannabis License RotoGro to acquire 100% of the issued share capital of Supra THC from Valens GroWorks Corp. ( CSE:VGW ) Supra THC holds a

More information

AGM Presentation For the year to 30 September February 2016

AGM Presentation For the year to 30 September February 2016 AGM Presentation For the year to 30 September 2015 25 February 2016 11 Forward Looking Statements This presentation includes forward-looking statements. These forward-looking statements involve known and

More information

- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes

- Plans Commercial Launch of three dosing options for Excellagen in pre-filled syringes Generex Biotechnology Subsidiary Olaregen Therapeutix Inc. Plans Launch of FDA Cleared Excellagen Wound Conforming Gel Matrix with Three Dosage Options - Plans Commercial Launch of three dosing options

More information

Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth

Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Valneva Reports Strong 2017 Revenues Driven by Double Digit Product Sales Growth Strong sales performance in 2017 (unaudited) Total revenues of 109.8 million in 2017 (2016-97.9 million) representing year-on-year

More information

Pierre Legault CEO June 2, 2014

Pierre Legault CEO June 2, 2014 April 2012 Pierre Legault CEO June 2, 2014 Forward Looking Statements This presentation includes statements that are, or may be deemed, forward-looking statements. In some cases, these forward-looking

More information

CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter)

CAN-FITE BIOPHARMA LTD. (Exact name of Registrant as specified in its charter) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 6-K Report of Foreign Private Issuer Pursuant to Rule 13a-16 or 15d-16 Under the Securities Exchange Act of 1934 For the Month

More information

Oncology Therapeutics without Compromise APRIL 2011

Oncology Therapeutics without Compromise APRIL 2011 Oncology Therapeutics without Compromise APRIL 2011 Forward Looking Statements This presentation contains forward-looking statements that involve substantial risks and uncertainties, including among other

More information

February 23, Q4 and Year-End 2016 Financial Results

February 23, Q4 and Year-End 2016 Financial Results February 23, 2017 Q4 and Year-End 2016 Financial Results 2 RETHINKING CNS Agenda Today s Speakers Paul Cox, Senior Director, Investor Relations Jeff Jonas, M.D., Chief Executive Officer Jim Doherty, Ph.D.,

More information

Developing & Commercializing Targeted Small Molecule Drugs in Cancer

Developing & Commercializing Targeted Small Molecule Drugs in Cancer Developing & Commercializing Targeted Small Molecule Drugs in Cancer SAFE HARBOR STATEMENT 2 Forward-looking statements made in the course of this presentation are made pursuant to the safe harbor provisions

More information

Cheers! Why the Future of Cannabis is in Beverages. TSXV:BEER

Cheers! Why the Future of Cannabis is in Beverages. TSXV:BEER Cheers! Why the Future of Cannabis is in Beverages TSXV:BEER www.hillstreetbeverages.com Forward Looking Statements, blah, blah, blah This Presentation may contain statements which constitute forward-looking

More information

Bobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference

Bobby W. Sandage, Jr., PhD President & Chief Executive Officer. Lazard Capital Markets 8 th Annual Healthcare Conference Bobby W. Sandage, Jr., PhD President & Chief Executive Officer Lazard Capital Markets 8 th Annual Healthcare Conference Statements in this presentation that are not descriptions of historical facts are

More information

Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017

Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Valneva Reports Strong Q1 Revenue Growth and Positive EBITDA Reaffirms Financial Guidance and Pipeline Outlook for 2017 Robust Q1 financial results confirming financial self-sustainability strategy Total

More information

N a s d a q : I N S Y

N a s d a q : I N S Y N a s d a q : I N S Y 0 Safe Harbor Statement This presentation contains both historical information and forward-looking statements. Forward-looking statements are based on management's current expectations

More information